Evoq Remedies Limited (BOM:543500)
India · Delayed Price · Currency is INR 2.880
-0.100 (-3.36%)
At close: Jan 22, 2026
Evoq Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2020 |
Operating Revenue | 372.64 | 117.57 | 40.53 | 203.9 | 167.83 | 100.25 | Upgrade |
Other Revenue | 34.65 | 24.15 | 22.57 | 60.23 | - | - | Upgrade |
| 407.29 | 141.71 | 63.09 | 264.13 | 167.83 | 100.25 | Upgrade | |
Revenue Growth (YoY) | 1585.10% | 124.62% | -76.11% | 57.38% | 67.42% | 10.50% | Upgrade |
Cost of Revenue | 366.79 | 130.83 | 15.66 | 193.28 | 138.05 | 78.62 | Upgrade |
Gross Profit | 40.5 | 10.89 | 47.43 | 70.85 | 29.78 | 21.63 | Upgrade |
Selling, General & Admin | 0.88 | 0.68 | 4.52 | 4.76 | 4.49 | 1.05 | Upgrade |
Other Operating Expenses | 20.59 | 8.44 | 36.73 | 43.19 | 10.66 | 11.04 | Upgrade |
Operating Expenses | 22.19 | 9.61 | 41.32 | 47.99 | 15.15 | 12.09 | Upgrade |
Operating Income | 18.31 | 1.28 | 6.12 | 22.86 | 14.63 | 9.54 | Upgrade |
Other Non Operating Income (Expenses) | - | - | -0 | -0.01 | -0.05 | -0 | Upgrade |
Pretax Income | 18.31 | 1.28 | 6.11 | 22.85 | 14.58 | 9.54 | Upgrade |
Income Tax Expense | 0.65 | 0.4 | 1.59 | 6.65 | 3.67 | 2.38 | Upgrade |
Net Income | 17.67 | 0.88 | 4.52 | 16.19 | 10.91 | 7.15 | Upgrade |
Net Income to Common | 17.67 | 0.88 | 4.52 | 16.19 | 10.91 | 7.15 | Upgrade |
Net Income Growth | - | -80.50% | -72.06% | 48.38% | 52.53% | 238382.33% | Upgrade |
Shares Outstanding (Basic) | 26 | 25 | 14 | 14 | 10 | 1 | Upgrade |
Shares Outstanding (Diluted) | 26 | 25 | 14 | 14 | 10 | 1 | Upgrade |
Shares Change (YoY) | 30.91% | 83.09% | - | 35.84% | 900.56% | 40.93% | Upgrade |
EPS (Basic) | 0.68 | 0.04 | 0.33 | 1.19 | 1.09 | 7.15 | Upgrade |
EPS (Diluted) | 0.68 | 0.04 | 0.33 | 1.19 | 1.09 | 7.15 | Upgrade |
EPS Growth | - | -89.27% | -72.27% | 9.17% | -84.75% | 169130.79% | Upgrade |
Free Cash Flow | 28.46 | -148.81 | 53.08 | -43.59 | -276.38 | 0.31 | Upgrade |
Free Cash Flow Per Share | 1.09 | -5.98 | 3.90 | -3.21 | -27.61 | 0.31 | Upgrade |
Gross Margin | 9.95% | 7.68% | 75.19% | 26.82% | 17.74% | 21.58% | Upgrade |
Operating Margin | 4.50% | 0.91% | 9.69% | 8.65% | 8.72% | 9.52% | Upgrade |
Profit Margin | 4.34% | 0.62% | 7.17% | 6.13% | 6.50% | 7.14% | Upgrade |
Free Cash Flow Margin | 6.99% | -105.01% | 84.13% | -16.50% | -164.68% | 0.31% | Upgrade |
EBITDA | 19.03 | 1.77 | 6.19 | 22.9 | - | - | Upgrade |
EBITDA Margin | 4.67% | 1.25% | 9.81% | 8.67% | - | - | Upgrade |
D&A For EBITDA | 0.71 | 0.49 | 0.07 | 0.04 | - | - | Upgrade |
EBIT | 18.31 | 1.28 | 6.12 | 22.86 | 14.63 | 9.54 | Upgrade |
EBIT Margin | 4.50% | 0.91% | 9.69% | 8.65% | 8.72% | 9.52% | Upgrade |
Effective Tax Rate | 3.52% | 31.20% | 26.01% | 29.12% | 25.17% | 25.00% | Upgrade |
Revenue as Reported | 407.29 | 141.71 | 63.09 | 264.13 | 167.83 | 100.25 | Upgrade |
Advertising Expenses | - | - | 3.74 | 2.58 | 2.62 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.